Examining the immune environment in different types of breast cancer
Role of the Immune Environment in Response to Therapy in Breast Cancer
This study looks at tissue samples from women with different types of breast cancer to see how the immune environment affects treatment responses.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Abramson Cancer Center at Penn Medicine Academic / other |
| Locations | 1 site (Philadelphia, Pennsylvania) |
| Trial ID | NCT05396612 on ClinicalTrials.gov |
What this trial studies
This observational study analyzes tissue samples from women with various types of breast cancer, specifically focusing on the immune environments of ER+HER2- breast cancers compared to triple-negative and HER2+ breast cancers. The study does not involve any randomization or changes to standard treatment protocols, and it collects personal health information from participants under a HIPAA waiver. The goal is to better understand how the immune environment influences therapy responses in these breast cancer subtypes.
Who should consider this trial
Good fit: Ideal candidates are women aged 18 and older with non-metastatic breast cancer who are undergoing surgical resection at the University of Pennsylvania Health System.
Not a fit: Patients who are male, children, or pregnant individuals will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies tailored to the immune profiles of different breast cancer types.
How similar studies have performed: Other studies have explored the immune environment in breast cancer, showing promising results, but this specific approach is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: Women 18 years of age or older with non-metastatic breast cancer undergoing surgical resection in the University of Pennsylvania Health System. Exclusion criteria: Males Children Pregnant individuals
Where this trial is running
Philadelphia, Pennsylvania
- Abramson Cancer Center — Philadelphia, Pennsylvania, United States (Recruiting)
Study contacts
- Principal investigator: Jennifer Zhang, MD — Abramson Cancer Center
- Study coordinator: Julia T. Lewandowski
- Email: Julia.Lewandowski@Pennmedicine.upenn.edu
- Phone: 215-662-2861
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.